SlideShare ist ein Scribd-Unternehmen logo
1 von 31
Downloaden Sie, um offline zu lesen
CAR-T:
Market Perspectives
April 15, 2015
Brand Acumen
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T: Market Positioning
2	
  
The purpose of this presentation is
to examine the CAR-T market
landscape with an eye on brand
positioning, market messaging and
current external perceptions.
The contents include a high level
overview of the nomenclature and
nascent brand architecture of the
primary companies, a review of the
evolving CAR-T lexicon, and the
results of a CAR-T specific Brand
Equity Perception Study conducted
in March, 2015 with 83
professionals.
Differentiation Dimensions
Overview:
The CAR-T
Nomenclature and
Nascent Brand
Architecture
Brand Acumen’s
CAR-T
Brand Equity
Perception Study
March, 2015
A Review of the
Evolving
CAR-T Lexicon
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
Celyad
Transposagen
Cellular Biomedicine
Carsgen
Unum
Caribou Biosciences
Xcyte
WuXi
Atara
CAR-T
émergent
nomenclature
corporatebrands
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
anewlexicon
chimeric antigen receptor therapy
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T: Brand Equity Perception Study
In terms of Market Positioning,
we shaped our external
questionnaire to reflect each of
the company's 'overall clarity of
communication' and asked "What
were the key drivers that made
each respective company stand
out amongst their peers."
In this study we examined six (6) key
categories for assessment. They are
as follows:
Category Attributes Explained
For the Web Presence analysis,
we examined the inherent
associative brand (corporate)
characteristics as they related to
CAR-T. (This was particularly
important as Novartis is different
then the others as it is the only
'Big Pharma' player in the study).
Web
Presence
Market
Positioning
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T: Brand Equity Perception Study
Collateral Material incorporates a
review of the analog (print, etc.) and
digital materials available from each of
the companies. We looked at the ease
of access to materials, educational
offerings, range and scope of the
materials and commitment to continue
to educate at various different
communication junctions (Patient,
HCP, etc.).
In terms of Differentiation, we focused
our assessment on many of the
traditional market differentiators and
the ability for each company to
leverage their core brand today and in
the future. Gauging these attributes
included asking: "How do you perceive
this company’s ability to deliver on the
promise put forth in their
communication?". "Will their therapy
work?". "Will they be first to market?”
"Who is best? Second Best? etc.
Category Attributes Explained
Differentiation
Collateral
Material
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T: Brand Equity Perception Study
Category Attributes Explained
Depth. Here we examined each
company's respective pipelines and
how this resonates back to the
corporate brand identity. This was
more of a focus for Wall Street, VC's,
investors and peers. Questions
included: "Who has the deepest
minds?". "Who has the least likelihood
to suffer from brand technological
obsolescence?”
Analysts Perception asserts a battery
of questions for Wall Street Analysts,
VC's, biotech savvy investors and
hedge fund analysts who understand
and track/invest in the CAR-T space.
Depth
Analyst
Perception
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”v
SurveyDesign
8	
  
To initiate the CAR-T Brand Equity
Study we surveyed five segments
of Key Innovation Leaders (KILs).
•  Bio Industry Writers (8)
•  Venture Capitalists (7)
•  Oncologists (35)
•  CAR-T Specific Researchers (21)
•  Market Makers/Analysts (12)
CAR-TBrandEquityPerceptionStudy
Brand Acumen’s CAR-T Brand Equity survey methodology brings together market,
brand, competitive, and technological attribute perceptions.
A corporate brand’s performance can be assessed allowing for a roadmap for
improvement to be identified in micro-niche biotech ecosystems.
samplesize/
numberofrespondents
Each of the six attribute
categories are scored from
0-100 with 0 being the lowest
and 100 the highest score.
The scores are weighted
based on respondents
answers to quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
chimeric antigen receptor therapy
CAR-T:
The Main Players
A Review of Company Nomenclature and
Results of the Brand Acumen CAR-T Brand Equity Perception Study
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
nomenclature
@NascentCAR-TNomenclature
tisagenlecleucel-T
Alternative Names:
•  Anti-CD19-CAR retroviral vector-transduced autologous T
cells - University of Pennsylvania
•  Anti-CD19-CAR transduced T cells - Novartis/University of
Pennsylvania
•  CART-019; CART-19; CART-19 cells
•  Chimeric antigen receptor-modified T cells against CD19 -
University of Pennsylvania/Novartis
•  CTL 019
•  LG-740
Most Recent Events
26 Feb 2015
Phase-II clinical trials in
Diffuse large B cell lymphoma
in USA (IV) (Novartis, pipeline,
February 2015)
08 Dec 2014 Efficacy data from
a pediatric study in Acute
lymphoblastic leukemia
presented at the 56th Annual
Meeting and Exposition of the
American Society of
Hematology (ASH-Hem-2014)
15 Oct 2014 Interim efficacy
and adverse events data from
two phase I trials in Acute
lymphoblastic leukemia
(second-line therapy or
greater) released by University
of Pennsylvania
tisa – gen – lec – leu – cel - T
generic name
•  MesoCART
•  huCART19
non-proprietary name
CRISPR/Cas9
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
nomenclature
@NascentCAR-TNomenclature
Sleeping Beauty
RheoSwitch®
platformbrands
AttSite®
UltraVector®
LEAP®
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
nomenclature
@NascentCAR-TNomenclature
Lentiglobin®
Lenti-D®
Starbeam Study
North Star Study
branded clinical studies
brands
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
CAR-T
nomenclature
@NascentCAR-TNomenclature
eACT™
T-Cell Factory B.V.
acquisition
collaboration
platformbrand
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
nomenclature
@NascentCAR-TNomenclature
CaspaCIDe™
CIDeCAR™
GoCAR-T™
DeCIDe™
brands
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
CAR-T
nomenclature
@NascentCAR-TNomenclature
Armored CAR technology
technology brand
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-T
nomenclature
@NascentCAR-TNomenclature
pipeline identifier brand
UCART
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six attribute categories are scored from 0-100 with 0 being
the lowest and 100 the highest score.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
CAR-TBrandEquityPerceptionStudy
Each of the six
attribute
categories are
scored from 0-100
with 0 being the
lowest and 100 the
highest score.
The scores are
weighted based on
respondents
answers to
quantitative and
qualitative criteria.
Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
evolutionary.
revolutionary.
disruptive.
31	
  Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”

Weitere ähnliche Inhalte

Was ist angesagt?

CANCER STEM CELLS
CANCER STEM CELLSCANCER STEM CELLS
CANCER STEM CELLSsathish sak
 
The immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontierThe immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontierThe ScientifiK
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapyNeha Patel
 
Apoptosis and the response to chemotherapy
Apoptosis and the response to chemotherapyApoptosis and the response to chemotherapy
Apoptosis and the response to chemotherapymeducationdotnet
 
Epidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinaseEpidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinaseGedion Yilma
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Emad Shash
 
Cell Therapy - Definitions and Classifications
Cell Therapy - Definitions and ClassificationsCell Therapy - Definitions and Classifications
Cell Therapy - Definitions and Classificationsnanog
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewEchoHan4
 
Conditioning regimen for haplo transplant
Conditioning regimen for haplo transplantConditioning regimen for haplo transplant
Conditioning regimen for haplo transplantspa718
 
TUMOR microenvironment
TUMOR microenvironment TUMOR microenvironment
TUMOR microenvironment AmitSamadhiya1
 
Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyMohamed Abdulla
 
Antibody Drug Conjugates: Structure, Safety & Stability
Antibody Drug Conjugates: Structure, Safety & StabilityAntibody Drug Conjugates: Structure, Safety & Stability
Antibody Drug Conjugates: Structure, Safety & StabilityPharmaxo
 
Cancer signal-transduction
Cancer signal-transductionCancer signal-transduction
Cancer signal-transductionDeepika Tripathi
 

Was ist angesagt? (20)

Car T cell
Car T cellCar T cell
Car T cell
 
CAR T cell.pptx
CAR T cell.pptxCAR T cell.pptx
CAR T cell.pptx
 
Car t cell tumor board
Car  t cell tumor boardCar  t cell tumor board
Car t cell tumor board
 
targeted therapy
targeted therapytargeted therapy
targeted therapy
 
CANCER STEM CELLS
CANCER STEM CELLSCANCER STEM CELLS
CANCER STEM CELLS
 
The immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontierThe immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontier
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Apoptosis and the response to chemotherapy
Apoptosis and the response to chemotherapyApoptosis and the response to chemotherapy
Apoptosis and the response to chemotherapy
 
Epidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinaseEpidermal growth factor and its receptor tyrosine kinase
Epidermal growth factor and its receptor tyrosine kinase
 
Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017Basics of cancer immunotherapy 2017
Basics of cancer immunotherapy 2017
 
Cell Therapy - Definitions and Classifications
Cell Therapy - Definitions and ClassificationsCell Therapy - Definitions and Classifications
Cell Therapy - Definitions and Classifications
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-review
 
Cancer vaccines
Cancer vaccinesCancer vaccines
Cancer vaccines
 
Conditioning regimen for haplo transplant
Conditioning regimen for haplo transplantConditioning regimen for haplo transplant
Conditioning regimen for haplo transplant
 
TUMOR microenvironment
TUMOR microenvironment TUMOR microenvironment
TUMOR microenvironment
 
Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in Oncology
 
Antibody Drug Conjugates: Structure, Safety & Stability
Antibody Drug Conjugates: Structure, Safety & StabilityAntibody Drug Conjugates: Structure, Safety & Stability
Antibody Drug Conjugates: Structure, Safety & Stability
 
Car T cell
Car T cellCar T cell
Car T cell
 
Cancer signal-transduction
Cancer signal-transductionCancer signal-transduction
Cancer signal-transduction
 

Andere mochten auch

CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya OzawaCAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawaspa718
 
Chimeric Antigen Receptors
Chimeric Antigen Receptors Chimeric Antigen Receptors
Chimeric Antigen Receptors Kevin B Hugins
 
CellTherapyTrends10
CellTherapyTrends10CellTherapyTrends10
CellTherapyTrends10nanog
 
CAR-T cell therapy in China
CAR-T cell therapy in ChinaCAR-T cell therapy in China
CAR-T cell therapy in Chinaspa718
 
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...Cell and Gene Therapy Catapult
 
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...Cell and Gene Therapy Catapult
 
Clinical development of cell-based therapies in the UK A presentation by Chie...
Clinical development of cell-based therapies in the UK A presentation by Chie...Clinical development of cell-based therapies in the UK A presentation by Chie...
Clinical development of cell-based therapies in the UK A presentation by Chie...Cell and Gene Therapy Catapult
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapyspa718
 
Cellular therapies in Acute Lymphocytic Leukemia
Cellular therapies in Acute Lymphocytic LeukemiaCellular therapies in Acute Lymphocytic Leukemia
Cellular therapies in Acute Lymphocytic Leukemiaspa718
 
The Cell Therapy Catapult: Keith Thompson CEO January 2013
The Cell Therapy Catapult: Keith Thompson CEO January 2013The Cell Therapy Catapult: Keith Thompson CEO January 2013
The Cell Therapy Catapult: Keith Thompson CEO January 2013Cell and Gene Therapy Catapult
 
World stem cell and regenerative medicine conference, london – may 2013
World stem cell and regenerative medicine conference, london – may 2013World stem cell and regenerative medicine conference, london – may 2013
World stem cell and regenerative medicine conference, london – may 2013Cell and Gene Therapy Catapult
 
Business-led Translation A presentation by CEO, Keith Thompson, about growing...
Business-led Translation A presentation by CEO, Keith Thompson, about growing...Business-led Translation A presentation by CEO, Keith Thompson, about growing...
Business-led Translation A presentation by CEO, Keith Thompson, about growing...Cell and Gene Therapy Catapult
 
Andre Radensky Sigma Xi
Andre Radensky Sigma XiAndre Radensky Sigma Xi
Andre Radensky Sigma Xiaradensky
 
Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)Kevin B Hugins
 
Industrialization of a stem cell process - How to identify the right Strategy...
Industrialization of a stem cell process - How to identify the right Strategy...Industrialization of a stem cell process - How to identify the right Strategy...
Industrialization of a stem cell process - How to identify the right Strategy...Fabien MONCAUBEIG
 
Ibc cell therapy clinical development conference (arlington va september 10 ...
Ibc cell therapy clinical development conference (arlington va  september 10 ...Ibc cell therapy clinical development conference (arlington va  september 10 ...
Ibc cell therapy clinical development conference (arlington va september 10 ...Proteus Venture Partners
 
RITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNRITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNAnil Vibhute
 
Tissue engg.
Tissue engg. Tissue engg.
Tissue engg. arushe143
 

Andere mochten auch (20)

CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya OzawaCAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
 
adoptive T cell therapy
adoptive T cell therapyadoptive T cell therapy
adoptive T cell therapy
 
Chimeric Antigen Receptors
Chimeric Antigen Receptors Chimeric Antigen Receptors
Chimeric Antigen Receptors
 
CellTherapyTrends10
CellTherapyTrends10CellTherapyTrends10
CellTherapyTrends10
 
CAR-T cell therapy in China
CAR-T cell therapy in ChinaCAR-T cell therapy in China
CAR-T cell therapy in China
 
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...
Autologous and Allogeneic Cell Therapy Industrialisation – Overcoming Clinica...
 
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...
Cell Therapy Catapult Manufacturing Solutions for cell-based ATMPs. A present...
 
Clinical development of cell-based therapies in the UK A presentation by Chie...
Clinical development of cell-based therapies in the UK A presentation by Chie...Clinical development of cell-based therapies in the UK A presentation by Chie...
Clinical development of cell-based therapies in the UK A presentation by Chie...
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapy
 
Cellular therapies in Acute Lymphocytic Leukemia
Cellular therapies in Acute Lymphocytic LeukemiaCellular therapies in Acute Lymphocytic Leukemia
Cellular therapies in Acute Lymphocytic Leukemia
 
The Cell Therapy Catapult: Keith Thompson CEO January 2013
The Cell Therapy Catapult: Keith Thompson CEO January 2013The Cell Therapy Catapult: Keith Thompson CEO January 2013
The Cell Therapy Catapult: Keith Thompson CEO January 2013
 
World stem cell and regenerative medicine conference, london – may 2013
World stem cell and regenerative medicine conference, london – may 2013World stem cell and regenerative medicine conference, london – may 2013
World stem cell and regenerative medicine conference, london – may 2013
 
Business-led Translation A presentation by CEO, Keith Thompson, about growing...
Business-led Translation A presentation by CEO, Keith Thompson, about growing...Business-led Translation A presentation by CEO, Keith Thompson, about growing...
Business-led Translation A presentation by CEO, Keith Thompson, about growing...
 
Andre Radensky Sigma Xi
Andre Radensky Sigma XiAndre Radensky Sigma Xi
Andre Radensky Sigma Xi
 
Day2
Day2Day2
Day2
 
Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
 
Industrialization of a stem cell process - How to identify the right Strategy...
Industrialization of a stem cell process - How to identify the right Strategy...Industrialization of a stem cell process - How to identify the right Strategy...
Industrialization of a stem cell process - How to identify the right Strategy...
 
Ibc cell therapy clinical development conference (arlington va september 10 ...
Ibc cell therapy clinical development conference (arlington va  september 10 ...Ibc cell therapy clinical development conference (arlington va  september 10 ...
Ibc cell therapy clinical development conference (arlington va september 10 ...
 
RITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGNRITUXIMAB PLANT DESIGN
RITUXIMAB PLANT DESIGN
 
Tissue engg.
Tissue engg. Tissue engg.
Tissue engg.
 

Ähnlich wie CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015

Updated Car-T Nomenclature Review & Brand Perception Study
Updated Car-T Nomenclature Review & Brand Perception StudyUpdated Car-T Nomenclature Review & Brand Perception Study
Updated Car-T Nomenclature Review & Brand Perception StudyBrand Acumen
 
CAR-T Nomenclature Review and Brand Perception Study
CAR-T Nomenclature Review and Brand Perception StudyCAR-T Nomenclature Review and Brand Perception Study
CAR-T Nomenclature Review and Brand Perception StudyBrand Acumen, LLC
 
Car t nomenclature and positioning-2
Car t nomenclature and positioning-2Car t nomenclature and positioning-2
Car t nomenclature and positioning-2Brand Acumen, LLC
 
Bio conference the case for naming sooner than later
Bio conference the case for naming sooner than laterBio conference the case for naming sooner than later
Bio conference the case for naming sooner than laterBrand Acumen, LLC
 
BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"
BIO Conference Upcoming Lecture"  "The Case for Naming Sooner ...Than Later"BIO Conference Upcoming Lecture"  "The Case for Naming Sooner ...Than Later"
BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"Bill Smith
 
Myriad genetics, inc. product pipeline analysis
Myriad genetics, inc.   product pipeline analysisMyriad genetics, inc.   product pipeline analysis
Myriad genetics, inc. product pipeline analysisraja1233
 
Pharmaceutical trademark impact study, 2015
Pharmaceutical trademark impact study, 2015 Pharmaceutical trademark impact study, 2015
Pharmaceutical trademark impact study, 2015 Brand Acumen, LLC
 
Oncology Intelligence Report 2014 Broucher
Oncology Intelligence Report 2014 BroucherOncology Intelligence Report 2014 Broucher
Oncology Intelligence Report 2014 BroucherOmicsX
 
Pharmaceutical trademark impact study
Pharmaceutical trademark impact studyPharmaceutical trademark impact study
Pharmaceutical trademark impact studyBrand Acumen
 
Pharmaceutical Trademark Impact Study December, 2018
Pharmaceutical Trademark Impact Study December, 2018Pharmaceutical Trademark Impact Study December, 2018
Pharmaceutical Trademark Impact Study December, 2018Brand Acumen, LLC
 
Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketOutsourcing in Drug Development: The Contract Research (Clinical Trial) Market
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
 
Carcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerCarcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerReports Corner
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015Ambikabasa
 
Immunetics, inc. product pipeline analysis
Immunetics, inc.   product pipeline analysisImmunetics, inc.   product pipeline analysis
Immunetics, inc. product pipeline analysisAarkstore Enterprise
 
Cook medical incorporated product pipeline analysis
Cook medical incorporated   product pipeline analysisCook medical incorporated   product pipeline analysis
Cook medical incorporated product pipeline analysisraja1233
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015Ambikabasa
 
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerEsophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerReports Corner
 
Ms dx, inc. product pipeline analysis
Ms dx, inc.   product pipeline analysisMs dx, inc.   product pipeline analysis
Ms dx, inc. product pipeline analysisAarkstore Enterprise
 
First light biosciences, inc. product pipeline analysis
First light biosciences, inc.   product pipeline analysisFirst light biosciences, inc.   product pipeline analysis
First light biosciences, inc. product pipeline analysisAarkstore Enterprise
 

Ähnlich wie CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015 (20)

Updated Car-T Nomenclature Review & Brand Perception Study
Updated Car-T Nomenclature Review & Brand Perception StudyUpdated Car-T Nomenclature Review & Brand Perception Study
Updated Car-T Nomenclature Review & Brand Perception Study
 
CAR-T Nomenclature Review and Brand Perception Study
CAR-T Nomenclature Review and Brand Perception StudyCAR-T Nomenclature Review and Brand Perception Study
CAR-T Nomenclature Review and Brand Perception Study
 
Car t nomenclature and positioning-2
Car t nomenclature and positioning-2Car t nomenclature and positioning-2
Car t nomenclature and positioning-2
 
Bio conference the case for naming sooner than later
Bio conference the case for naming sooner than laterBio conference the case for naming sooner than later
Bio conference the case for naming sooner than later
 
BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"
BIO Conference Upcoming Lecture"  "The Case for Naming Sooner ...Than Later"BIO Conference Upcoming Lecture"  "The Case for Naming Sooner ...Than Later"
BIO Conference Upcoming Lecture" "The Case for Naming Sooner ...Than Later"
 
Myriad genetics, inc. product pipeline analysis
Myriad genetics, inc.   product pipeline analysisMyriad genetics, inc.   product pipeline analysis
Myriad genetics, inc. product pipeline analysis
 
Pharmaceutical trademark impact study, 2015
Pharmaceutical trademark impact study, 2015 Pharmaceutical trademark impact study, 2015
Pharmaceutical trademark impact study, 2015
 
Oncology Intelligence Report 2014 Broucher
Oncology Intelligence Report 2014 BroucherOncology Intelligence Report 2014 Broucher
Oncology Intelligence Report 2014 Broucher
 
Pharmaceutical trademark impact study
Pharmaceutical trademark impact studyPharmaceutical trademark impact study
Pharmaceutical trademark impact study
 
Pharmaceutical Trademark Impact Study December, 2018
Pharmaceutical Trademark Impact Study December, 2018Pharmaceutical Trademark Impact Study December, 2018
Pharmaceutical Trademark Impact Study December, 2018
 
Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketOutsourcing in Drug Development: The Contract Research (Clinical Trial) Market
Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market
 
Carcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports CornerCarcinomas – pipeline review, h1 2013 - Reports Corner
Carcinomas – pipeline review, h1 2013 - Reports Corner
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015
 
Immunetics, inc. product pipeline analysis
Immunetics, inc.   product pipeline analysisImmunetics, inc.   product pipeline analysis
Immunetics, inc. product pipeline analysis
 
Cook medical incorporated product pipeline analysis
Cook medical incorporated   product pipeline analysisCook medical incorporated   product pipeline analysis
Cook medical incorporated product pipeline analysis
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015
 
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports CornerEsophageal cancer – pipeline review, h1 2013 - Reports Corner
Esophageal cancer – pipeline review, h1 2013 - Reports Corner
 
Ms dx, inc. product pipeline analysis
Ms dx, inc.   product pipeline analysisMs dx, inc.   product pipeline analysis
Ms dx, inc. product pipeline analysis
 
First light biosciences, inc. product pipeline analysis
First light biosciences, inc.   product pipeline analysisFirst light biosciences, inc.   product pipeline analysis
First light biosciences, inc. product pipeline analysis
 
Vulvar Cancer - Pipeline Insight, 2018
Vulvar Cancer - Pipeline Insight, 2018Vulvar Cancer - Pipeline Insight, 2018
Vulvar Cancer - Pipeline Insight, 2018
 

Mehr von Bill Smith

USAN Complete.pptx
USAN Complete.pptxUSAN Complete.pptx
USAN Complete.pptxBill Smith
 
UNICEF Brand Standards Manual.pdf
UNICEF Brand Standards Manual.pdfUNICEF Brand Standards Manual.pdf
UNICEF Brand Standards Manual.pdfBill Smith
 
Beer - Name Development Drives Product Innovation.pdf
Beer - Name Development Drives Product Innovation.pdfBeer - Name Development Drives Product Innovation.pdf
Beer - Name Development Drives Product Innovation.pdfBill Smith
 
ACC Brand Standards Manual 2.pdf
ACC Brand Standards Manual 2.pdfACC Brand Standards Manual 2.pdf
ACC Brand Standards Manual 2.pdfBill Smith
 
Brand Acumen Case Studies 30 Years of Defining Names.pdf
Brand Acumen Case Studies 30 Years of Defining Names.pdfBrand Acumen Case Studies 30 Years of Defining Names.pdf
Brand Acumen Case Studies 30 Years of Defining Names.pdfBill Smith
 
The Global Innovation Index, 2015
The Global Innovation Index, 2015The Global Innovation Index, 2015
The Global Innovation Index, 2015Bill Smith
 
ACC (Atlantic Coast Conference) Brand Standards Manual
ACC (Atlantic Coast Conference) Brand Standards ManualACC (Atlantic Coast Conference) Brand Standards Manual
ACC (Atlantic Coast Conference) Brand Standards ManualBill Smith
 
Brand Naming: Linguistic Analysis Terms Defined
Brand Naming: Linguistic Analysis Terms DefinedBrand Naming: Linguistic Analysis Terms Defined
Brand Naming: Linguistic Analysis Terms DefinedBill Smith
 
Estee Lauder Namie Development: Luminist
Estee Lauder Namie Development:  Luminist Estee Lauder Namie Development:  Luminist
Estee Lauder Namie Development: Luminist Bill Smith
 
KFC Brand Standards Manual
KFC Brand Standards ManualKFC Brand Standards Manual
KFC Brand Standards ManualBill Smith
 
Genome Canada Brand Standards Guide
Genome Canada Brand Standards GuideGenome Canada Brand Standards Guide
Genome Canada Brand Standards GuideBill Smith
 
Duke Energy Brand Standards Manual
Duke Energy Brand Standards ManualDuke Energy Brand Standards Manual
Duke Energy Brand Standards ManualBill Smith
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
European Medicines Agency: Good Practice Guide
European Medicines Agency: Good Practice GuideEuropean Medicines Agency: Good Practice Guide
European Medicines Agency: Good Practice GuideBill Smith
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...Bill Smith
 
Pharmaceutical Naming: A Guide to USAN/INN Review Procedures
Pharmaceutical Naming: A Guide to USAN/INN Review ProceduresPharmaceutical Naming: A Guide to USAN/INN Review Procedures
Pharmaceutical Naming: A Guide to USAN/INN Review ProceduresBill Smith
 
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Bill Smith
 
Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015Bill Smith
 
Ingredient Branding
Ingredient BrandingIngredient Branding
Ingredient BrandingBill Smith
 

Mehr von Bill Smith (20)

USAN Complete.pptx
USAN Complete.pptxUSAN Complete.pptx
USAN Complete.pptx
 
UNICEF Brand Standards Manual.pdf
UNICEF Brand Standards Manual.pdfUNICEF Brand Standards Manual.pdf
UNICEF Brand Standards Manual.pdf
 
Beer - Name Development Drives Product Innovation.pdf
Beer - Name Development Drives Product Innovation.pdfBeer - Name Development Drives Product Innovation.pdf
Beer - Name Development Drives Product Innovation.pdf
 
ACC Brand Standards Manual 2.pdf
ACC Brand Standards Manual 2.pdfACC Brand Standards Manual 2.pdf
ACC Brand Standards Manual 2.pdf
 
Brand Acumen Case Studies 30 Years of Defining Names.pdf
Brand Acumen Case Studies 30 Years of Defining Names.pdfBrand Acumen Case Studies 30 Years of Defining Names.pdf
Brand Acumen Case Studies 30 Years of Defining Names.pdf
 
The Global Innovation Index, 2015
The Global Innovation Index, 2015The Global Innovation Index, 2015
The Global Innovation Index, 2015
 
ACC (Atlantic Coast Conference) Brand Standards Manual
ACC (Atlantic Coast Conference) Brand Standards ManualACC (Atlantic Coast Conference) Brand Standards Manual
ACC (Atlantic Coast Conference) Brand Standards Manual
 
Brand Naming: Linguistic Analysis Terms Defined
Brand Naming: Linguistic Analysis Terms DefinedBrand Naming: Linguistic Analysis Terms Defined
Brand Naming: Linguistic Analysis Terms Defined
 
Estee Lauder Namie Development: Luminist
Estee Lauder Namie Development:  Luminist Estee Lauder Namie Development:  Luminist
Estee Lauder Namie Development: Luminist
 
KFC Brand Standards Manual
KFC Brand Standards ManualKFC Brand Standards Manual
KFC Brand Standards Manual
 
Genome Canada Brand Standards Guide
Genome Canada Brand Standards GuideGenome Canada Brand Standards Guide
Genome Canada Brand Standards Guide
 
Duke Energy Brand Standards Manual
Duke Energy Brand Standards ManualDuke Energy Brand Standards Manual
Duke Energy Brand Standards Manual
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
European Medicines Agency: Good Practice Guide
European Medicines Agency: Good Practice GuideEuropean Medicines Agency: Good Practice Guide
European Medicines Agency: Good Practice Guide
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Bios...
 
Pharmaceutical Naming: A Guide to USAN/INN Review Procedures
Pharmaceutical Naming: A Guide to USAN/INN Review ProceduresPharmaceutical Naming: A Guide to USAN/INN Review Procedures
Pharmaceutical Naming: A Guide to USAN/INN Review Procedures
 
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...
Guide to Online International Non-Proprietary Name (INN) Electronic Name Subm...
 
Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015
 
Ingredient Branding
Ingredient BrandingIngredient Branding
Ingredient Branding
 

Kürzlich hochgeladen

MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentationbaron83
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003believeminhh
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxesiyasmengesha
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toumarfarooquejamali32
 
Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsIntellect Design Arena Ltd
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhangmcgroupjeya
 
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessQ2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessAPCO
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKELtd
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
Scrum Events & How to run them effectively
Scrum Events & How to run them effectivelyScrum Events & How to run them effectively
Scrum Events & How to run them effectivelyMarianna Nakou
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBBPMedia1
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..dlewis191
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyHanna Klim
 

Kürzlich hochgeladen (20)

MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
 
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
Boat Trailers Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptxChapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
Chapter_Five_The_Rural_Development_Policies_and_Strategy_of_Ethiopia.pptx
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb to
 
Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking Applications
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhang
 
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessQ2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
ISONIKE Ltd Accreditation for the Conformity Assessment and Certification of ...
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
Scrum Events & How to run them effectively
Scrum Events & How to run them effectivelyScrum Events & How to run them effectively
Scrum Events & How to run them effectively
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
 
Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..Team B Mind Map for Organizational Chg..
Team B Mind Map for Organizational Chg..
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agency
 

CAR-T (Cell Therapy) Nomenclature Review & Brand Equity Study. April 15, 2015

  • 1. CAR-T: Market Perspectives April 15, 2015 Brand Acumen Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 2. CAR-T: Market Positioning 2   The purpose of this presentation is to examine the CAR-T market landscape with an eye on brand positioning, market messaging and current external perceptions. The contents include a high level overview of the nomenclature and nascent brand architecture of the primary companies, a review of the evolving CAR-T lexicon, and the results of a CAR-T specific Brand Equity Perception Study conducted in March, 2015 with 83 professionals. Differentiation Dimensions Overview: The CAR-T Nomenclature and Nascent Brand Architecture Brand Acumen’s CAR-T Brand Equity Perception Study March, 2015 A Review of the Evolving CAR-T Lexicon Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 4. CAR-T anewlexicon chimeric antigen receptor therapy Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 5. CAR-T: Brand Equity Perception Study In terms of Market Positioning, we shaped our external questionnaire to reflect each of the company's 'overall clarity of communication' and asked "What were the key drivers that made each respective company stand out amongst their peers." In this study we examined six (6) key categories for assessment. They are as follows: Category Attributes Explained For the Web Presence analysis, we examined the inherent associative brand (corporate) characteristics as they related to CAR-T. (This was particularly important as Novartis is different then the others as it is the only 'Big Pharma' player in the study). Web Presence Market Positioning Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 6. CAR-T: Brand Equity Perception Study Collateral Material incorporates a review of the analog (print, etc.) and digital materials available from each of the companies. We looked at the ease of access to materials, educational offerings, range and scope of the materials and commitment to continue to educate at various different communication junctions (Patient, HCP, etc.). In terms of Differentiation, we focused our assessment on many of the traditional market differentiators and the ability for each company to leverage their core brand today and in the future. Gauging these attributes included asking: "How do you perceive this company’s ability to deliver on the promise put forth in their communication?". "Will their therapy work?". "Will they be first to market?” "Who is best? Second Best? etc. Category Attributes Explained Differentiation Collateral Material Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 7. CAR-T: Brand Equity Perception Study Category Attributes Explained Depth. Here we examined each company's respective pipelines and how this resonates back to the corporate brand identity. This was more of a focus for Wall Street, VC's, investors and peers. Questions included: "Who has the deepest minds?". "Who has the least likelihood to suffer from brand technological obsolescence?” Analysts Perception asserts a battery of questions for Wall Street Analysts, VC's, biotech savvy investors and hedge fund analysts who understand and track/invest in the CAR-T space. Depth Analyst Perception Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”v
  • 8. SurveyDesign 8   To initiate the CAR-T Brand Equity Study we surveyed five segments of Key Innovation Leaders (KILs). •  Bio Industry Writers (8) •  Venture Capitalists (7) •  Oncologists (35) •  CAR-T Specific Researchers (21) •  Market Makers/Analysts (12) CAR-TBrandEquityPerceptionStudy Brand Acumen’s CAR-T Brand Equity survey methodology brings together market, brand, competitive, and technological attribute perceptions. A corporate brand’s performance can be assessed allowing for a roadmap for improvement to be identified in micro-niche biotech ecosystems. samplesize/ numberofrespondents Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 9. chimeric antigen receptor therapy CAR-T: The Main Players A Review of Company Nomenclature and Results of the Brand Acumen CAR-T Brand Equity Perception Study Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 10. CAR-T nomenclature @NascentCAR-TNomenclature tisagenlecleucel-T Alternative Names: •  Anti-CD19-CAR retroviral vector-transduced autologous T cells - University of Pennsylvania •  Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania •  CART-019; CART-19; CART-19 cells •  Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis •  CTL 019 •  LG-740 Most Recent Events 26 Feb 2015 Phase-II clinical trials in Diffuse large B cell lymphoma in USA (IV) (Novartis, pipeline, February 2015) 08 Dec 2014 Efficacy data from a pediatric study in Acute lymphoblastic leukemia presented at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2014) 15 Oct 2014 Interim efficacy and adverse events data from two phase I trials in Acute lymphoblastic leukemia (second-line therapy or greater) released by University of Pennsylvania tisa – gen – lec – leu – cel - T generic name •  MesoCART •  huCART19 non-proprietary name CRISPR/Cas9 Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 11. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 12. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 14. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 15. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 16. CAR-T nomenclature @NascentCAR-TNomenclature Lentiglobin® Lenti-D® Starbeam Study North Star Study branded clinical studies brands Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 17. CAR-TBrandEquityPerceptionStudy Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 18. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
  • 19. CAR-T nomenclature @NascentCAR-TNomenclature eACT™ T-Cell Factory B.V. acquisition collaboration platformbrand Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 20. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 21. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 23. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 24. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria.
  • 25. CAR-T nomenclature @NascentCAR-TNomenclature Armored CAR technology technology brand Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 26. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 27. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 28. CAR-T nomenclature @NascentCAR-TNomenclature pipeline identifier brand UCART Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 29. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 30. CAR-TBrandEquityPerceptionStudy Each of the six attribute categories are scored from 0-100 with 0 being the lowest and 100 the highest score. The scores are weighted based on respondents answers to quantitative and qualitative criteria. Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”
  • 31. evolutionary. revolutionary. disruptive. 31  Brand Acumen. “The Global Leader in Pharmaceutical Name Development and Submissions”